Mechanism based neurotoxicity of mGlu5 positive allosteric modulators – Development challenges for a promising novel antipsychotic target

[1]  M. Bear,et al.  Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice , 2012, Neuron.

[2]  Jeffrey S. Smith,et al.  Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator. , 2011, European journal of pharmacology.

[3]  Sarah L. Huszar,et al.  MK-801 produces a deficit in sucrose preference that is reversed by clozapine, d-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: Relevance to negative symptoms associated with schizophrenia? , 2010, Pharmacology Biochemistry and Behavior.

[4]  W. Danysz,et al.  Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia , 2010, Pharmacology Biochemistry and Behavior.

[5]  P. Conn,et al.  Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.

[6]  Stephen M. Fitzjohn,et al.  Metabotropic Glutamate Receptor-Mediated Long-Term Depression: Molecular Mechanisms , 2009, Pharmacological Reviews.

[7]  J. Uslaner,et al.  Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus , 2009, Neuropharmacology.

[8]  F. Liu,et al.  ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities , 2008, Journal of Pharmacology and Experimental Therapeutics.

[9]  R. Ravazzolo,et al.  Presynaptic mGlu1 and mGlu5 autoreceptors facilitate glutamate exocytosis from mouse cortical nerve endings , 2008, Neuropharmacology.

[10]  C. Lüscher,et al.  Mechanisms of synaptic depression triggered by metabotropic glutamate receptors , 2008, Cellular and Molecular Life Sciences.

[11]  B. Moghaddam,et al.  Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. , 2008, Behavioural pharmacology.

[12]  M. Chan,et al.  Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice , 2008, Psychopharmacology.

[13]  Mark F. Bear,et al.  Correction of Fragile X Syndrome in Mice , 2007, Neuron.

[14]  Brett Connolly,et al.  Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. , 2007, Nuclear medicine and biology.

[15]  J. Fadel,et al.  Acute stress‐mediated increases in extracellular glutamate levels in the rat amygdala: differential effects of antidepressant treatment , 2007, The European journal of neuroscience.

[16]  J. Pin,et al.  Interaction of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 with the Negative Allosteric Antagonist Site Is Required for Potentiation of Receptor Responses , 2007, Molecular Pharmacology.

[17]  D. Balschun,et al.  Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory , 2006, Neuroscience.

[18]  S. Tsai,et al.  Polymorphisms in glycine transporter with schizophrenia. , 2006, Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology.

[19]  J. Sweatt,et al.  Signal transduction mechanisms in memory disorders. , 2006, Progress in brain research.

[20]  D. Manahan‐Vaughan,et al.  The metabotropic glutamate receptor, mGluR5, is a key determinant of good and bad spatial learning performance and hippocampal synaptic plasticity. , 2005, Cerebral cortex.

[21]  T. Schachtman,et al.  The role of metabotropic glutamate receptor 5 in learning and memory processes. , 2005, Drug news & perspectives.

[22]  C. Lindsley,et al.  A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models , 2005, Journal of Pharmacology and Experimental Therapeutics.

[23]  P Jeffrey Conn,et al.  Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. , 2004, Journal of medicinal chemistry.

[24]  P. Sanna,et al.  The metabotropic glutamate receptor 5 is necessary for late-phase long-term potentiation in the hippocampal CA1 region , 2004, Brain Research.

[25]  P Jeffrey Conn,et al.  A Novel Selective Allosteric Modulator Potentiates the Activity of Native Metabotropic Glutamate Receptor Subtype 5 in Rat Forebrain , 2004, Journal of Pharmacology and Experimental Therapeutics.

[26]  P. Conn,et al.  Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in Rodents , 2003, Journal of Pharmacology and Experimental Therapeutics.

[27]  B. Platt,et al.  Glutamate receptor function in learning and memory , 2003, Behavioural Brain Research.

[28]  P. Conn,et al.  Differential regulation of metabotropic glutamate receptor 5‐mediated phosphoinositide hydrolysis and extracellular signal‐regulated kinase responses by protein kinase C in cultured astrocytes , 2002, Journal of neurochemistry.

[29]  D. Javitt,et al.  Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. , 2002, The American journal of psychiatry.

[30]  A. Christopoulos.  Allosteric binding sites on cell-surface receptors: novel targets for drug discovery , 2002, Nature Reviews Drug Discovery.

[31]  R A Challiss,et al.  Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. , 2001, The Biochemical journal.

[32]  C. Tamminga,et al.  Effects of Ketamine in Normal and Schizophrenic Volunteers , 2001, Neuropsychopharmacology.

[33]  S. Traynelis,et al.  Metabotropic Glutamate Receptors 1 and 5 Differentially Regulate CA1 Pyramidal Cell Function , 2001, The Journal of Neuroscience.

[34]  J. Virkkala,et al.  The relationship between audiogenic seizure (AGS) susceptibility and forebrain tone-responsiveness in genetically AGS-prone Wistar rats , 2000, Physiology & Behavior.

[35]  D. Manahan‐Vaughan,et al.  Novelty acquisition is associated with induction of hippocampal long-term depression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Javitt,et al.  Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. , 1999, Archives of general psychiatry.

[37]  Nicholas Lange,et al.  D-serine added to antipsychotics for the treatment of schizophrenia , 1998, Biological Psychiatry.

[38]  N. O. Dalby,et al.  Roles of metabotropic glutamate receptor subtypes in modulation of pentylenetetrazole-induced seizure activity in mice , 1998, Neuropharmacology.

[39]  J. Roder,et al.  Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. , 1998, Learning & memory.

[40]  L. Camón,et al.  Seizures and neuronal damage induced in the rat by activation of group I metabotropic glutamate receptors with their selective agonist 3,5‐dihydroxyphenylglycine , 1998, Journal of neuroscience research.

[41]  S. Heinemann,et al.  Role of Protein Kinase C Phosphorylation in Rapid Desensitization of Metabotropic Glutamate Receptor 5 , 1998, Neuron.

[42]  J. Roder,et al.  Mice Lacking Metabotropic Glutamate Receptor 5 Show Impaired Learning and Reduced CA1 Long-Term Potentiation (LTP) But Normal CA3 LTP , 1997, The Journal of Neuroscience.

[43]  B. Moghaddam,et al.  Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam , 1997, Neuroscience.

[44]  D. Javitt,et al.  Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia , 1996, British Journal of Psychiatry.

[45]  A. N. van den Pol,et al.  Enhanced early developmental expression of the metabotropic glutamate receptor mGluR5 in rat brain: Protein, mRNA splice variants, and regional distribution , 1996, The Journal of comparative neurology.

[46]  D. Schoepp,et al.  Induction or protection of limbic seizures in mice by mGluR subtype selective agonists , 1995, Neuropharmacology.

[47]  B. Yamamoto,et al.  Effect of Acute Stress on Hippocampal Glutamate Levels and Spectrin Proteolysis in Young and Aged Rats , 1995, Journal of neurochemistry.

[48]  R. Duvoisin,et al.  The metabotropic glutamate receptors: Structure and functions , 1995, Neuropharmacology.

[49]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[50]  R. Balázs,et al.  Mechanisms underlying developmental changes in the expression of metabotropic glutamate receptors in cultured cerebellar granule cells: homologous desensitization and interactive effects involving N-methyl-D-aspartate receptors. , 1993, Molecular pharmacology.

[51]  H. Sugiyama,et al.  3,5-Dihydroxyphenyl-glycine: a potent agonist of metabotropic glutamate receptors. , 1992, Neuroreport.

[52]  D. Schoepp,et al.  Activation of hippocampal metabotropic excitatory amino acid receptors leads to seizures and neuronal damage , 1992, Neuroscience Letters.

[53]  D. Javitt,et al.  Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. , 1987, The Hillside journal of clinical psychiatry.

[54]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .